The recent CMS coverage determination did not make any mention of beta-amyloid PET imaging that is necessary for both diagnosing Alzheimer’s and monitoring the effectiveness of related treatments.
The findings support adopting F-18 DCFPyL PET/CT as the standard of care for prostate cancer staging, authors of a new Scientific Reports paper concluded.
Rather than administering radiolabeled glucose for exams, imagers give patients a small amount of a harmless glucose solution that is said to be equivalent to a can of a carbonated drink.
Difficulty obtaining PET/CT scans was reported by 55% of respondents, with 21% citing this as the greatest barrier in treating classic Hodgkin lymphoma.
The recent CMS coverage determination did not make any mention of beta-amyloid PET imaging that is necessary for both diagnosing Alzheimer’s and monitoring the effectiveness of related treatments.
The findings support adopting F-18 DCFPyL PET/CT as the standard of care for prostate cancer staging, authors of a new Scientific Reports paper concluded.
Rather than administering radiolabeled glucose for exams, imagers give patients a small amount of a harmless glucose solution that is said to be equivalent to a can of a carbonated drink.
Difficulty obtaining PET/CT scans was reported by 55% of respondents, with 21% citing this as the greatest barrier in treating classic Hodgkin lymphoma.
The AUC includes a total of 32 clinical scenarios that have been grouped into four categories of cancer: breast, skin, cancer of other sites and lymphedema.
